PTC Therapeutics, Inc.

PTCT Healthcare Biotechnology

PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.

Revenue
+69.6%
EPS
−409.7%
Free cash flow
+90.3%
Total debt
+19.3%

Quarter to September 2026, against a year earlier

65.55 0.12 −0.18%
Market cap
$5.5B
P/E
0.0×
Fwd P/E
42.2×
Dividend yield
—
F-score
7/9
Altman Z
1.86
Beneish M
−1.48
Dividend safety
n/a
Older periods Dec '25 Mar '26 Jun '26 Sep '26
ROE

+8 more TTM periods

(104.75%) 101.97% 20.64% 61.08%
Piotroski F-Score
7 1 2 3
ROA
29.66% (6.76%) (1.30%) (3.62%)
ROIC
121.13% (6.74%) 15.16% 17.66%
Return on Tangible Assets
50.16% (13.50%) (2.02%) (5.85%)
Average Days of Receivables
38.30 97.05 86.49 75.20
Free Cash Flow per Share
8.83 (5.85) (3.62) (3.10)
Free Cash Flow
702.41 (482.67) (300.25) (259.16)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 6 Nov 2026